Search results
AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
Reuters via AOL· 7 days agoRinvoq helped 19.9% of patients simultaneously achieve near-complete skin clearance with a...
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study By...
Investing.com· 6 days agoAbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
AbbVie announces LEVEL UP results in atopic dermatitis study By Investing.com
Investing.com· 7 days agoThe study focused on adult and adolescent patients who had an inadequate response to systemic...
AbbVie (ABBV) Could Be a Great Choice
Zacks via Yahoo Finance· 2 days agoDividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?...
AbbVie Reports First-Quarter 2024 Financial Results
The Hannibal Courier-Post· 6 days agoReports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent; These Results Include an Unfavorable
REFILE-AbbVie's Rinvoq shows superiority to Regeneron's Dupixent in study
Reuters via Yahoo Finance· 7 days ago(Corrects to remove extraneous text and to add Regeneron ticker symbol) April 25 (Reuters) - AbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory ...
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie
Zacks via Yahoo Finance· 7 days agoThe Zacks Consensus Estimate for Lilly's 2024 EPS has risen from $12.40 per share to $12.52 over the...
Lower CVD Risk With Stable DMARD Therapy in Seropositive RA
Medscape· 36 minutes agoPatients with seropositive RA on stable DMARD therapy showed a CVD risk comparable with that of the...
Trials to watch: Four ALS drugs to keep an eye on
Clinical Trials Arena via Yahoo Finance· 2 days agoHEALEY Platform trial investigates Calico and AbbVie drug The HEALEY ALS Platform Trial (NCT04297683) is a perpetual multi-centre... is a Phase II/III...
Addex stock tanks after lead drug flops in Phase II epilepsy trial
Clinical Trials Arena via Yahoo Finance· 2 days agoThe use of PAMs for treating neurological disorders has been an area of focus in recent months. In...